Digital biomarkers for every pathology
Modelling symptoms that cannot be measured remotely or objectively today
Biomarkers measure indicators of normal biological processes, pathogenic processes, or responses to an exposure or intervention. If this biomarker is collected using a digital sensing product, it’s known as a digital biomarker. If this sensing product captures speech, we call it a speech biomarker.
ki:elements biomarkers are not specified to indications but measure symptoms across indications – one biomarker serves multiple pathologies.
Disease agnostic, low-burden & scalable
Speech biomarkers work remotely, automatically, and are low-burden
Speech biomarkers have the advantage of being fully functional in remote settings without the need of any specific hardware, technique or even invasive procedures making them highly scalable and very cost-effective. The probe of speech needed can be collected with very low burden for patients or study participants resulting in incomparable patient compliance — in pre-screening, as trial endpoint or in drug companion use cases.
| ki:e speech biomarkers | Blood biomarkers | Imaging biomarkers | Clinical (rating) scale | |
|---|---|---|---|---|
|
Cost-effective |
⬤ ⬤ ⬤ ⬤ ⬤ |
⬤ ⬤ ⬤ |
⬤ |
⬤ ⬤ ⬤ |
|
Fast implementation |
⬤ ⬤ ⬤ ⬤ ⬤ |
⬤ ⬤ ⬤ |
⬤ |
⬤ |
|
Non-invasive |
⬤ ⬤ ⬤ ⬤ ⬤ |
⬤ |
⬤ |
⬤ ⬤ ⬤ ⬤ ⬤ |
|
Patient compliance |
⬤ ⬤ ⬤ ⬤ ⬤ |
⬤ |
⬤ |
⬤ ⬤ ⬤ |
|
Scalable |
⬤ ⬤ ⬤ ⬤ ⬤ |
⬤ ⬤ ⬤ |
⬤ |
⬤ |
Use case example: Pre-screening in AD
Enrollment as key barrier for AD trials
80%
of trails fail to meet enrollment timelines
30%
of clinical trial's timeline is spent on patient recruitment
$5.9B
spent annually on clinical trial recruitment
5%
or less of potential candidates enrolled in clinical trials
Using ki:e SB-C will significantly reduce the number of candidates invited to sites for screening and improve successful screen-in rate.
Biomarker example: validity of the ki:e SB-C biomarker
Under the hood of pre-screening — psychometric properties of ki:e SB-C
correlation with the MMSE
Strong correlation of the ki:e SB-C biomarker with MMSE total score.
discriminating between stages
Significant group differences between dementia, MCI and HC.
Better than the sum of it
Scientifically backed and co-developed with leading experts
ki:e speech biomarkers are built upon groundbreaking peer-reviewed scientific results across the fields of clinical neuropsychology, ageing neuroscience, machine learning and natural language processing.
>> more than 50 publications
>> involved in more than 30 studies
>> more than 5 years of research & experience
>> 8 active TAs
>> 2.7x YOY growth
>> 8 supported languages
… as well as 2 of the 5 top pharma companies in the world and many university clinics all over Europe.
Shape the future of health
Inspire & get inspired
Nicklas
Linz
CEO
data Scientist
Dr. Johannes
Tröger
CSO
Psychologist
Janna
Herrmann
CTO
Computer Scientist
Dr. Alexandra
König
Clinical Research Coordinator
Dr. Duy
Truong
Computer Scientist
Jannic
Warken
Computer Scientist
Mario
Mina
Data Scientist
Louisa
Schwed
data Scientist
Dr. Jian
Zhao
Regulatory Compliance Manager
Elisa
Mallick
data scientist
Daniel
Kettering
System Engineer
John
Nonnenmacher
Signal Processing Engineer
Simona
Schäfer
scientist
Sol
Tovar
Research Assistant
Christian
Guggemos
Management assistant
